Location History:
- Salt Lake City, UT (US) (1997)
- Newark, CA (US) (2001 - 2002)
- Encinitas, CA (US) (2002 - 2003)
- Titusville, NJ (US) (2005)
Company Filing History:
2 out of 1,645 
1 out of 789 
4 out of 832,843 Years Active: 1997-2005
Title: Mark E Curran: Innovator in Genetic Research
Introduction
Mark E Curran is a notable inventor based in Encinitas, California. He has made significant contributions to the field of genetic research, particularly in relation to long QT syndrome. With a total of six patents to his name, Curran's work has advanced the understanding of genetic mutations and their implications for health.
Latest Patents
Among his latest patents is the groundbreaking work on KVLQT1, a gene associated with long QT syndrome. This patent discloses the genomic structure, including the sequence of the intron/exon junctions for KVLQT1 and KCNE1. Additionally, it reveals newly found mutations in KVLQT1 that result in long QT syndrome. The intron/exon junction sequence data enable the design of primer pairs to amplify and sequence across all exons of these genes. This technology can be utilized to screen individuals for mutations that cause long QT syndrome. Furthermore, assays can be performed to detect mutations in either DNA or proteins. The DNA and proteins may also be employed in assays to identify drugs that could be effective in treating or preventing long QT syndrome.
Career Highlights
Curran has had a distinguished career, contributing to various research initiatives. His work has been instrumental in enhancing the understanding of genetic disorders and their treatment options.
Collaborations
Throughout his career, Curran has collaborated with notable individuals such as Mark T Keating and Michael C Sanguinetti. These collaborations have further enriched his research and innovation in the field.
Conclusion
Mark E Curran's contributions to genetic research, particularly in relation to long QT syndrome, highlight his role as a significant inventor in the field. His patents and collaborative efforts continue to pave the way for advancements in genetic screening and treatment.